Hikal Q3 FY26: Revenue, EBITDA surge amid regulatory recovery
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The revenues this quarter are in line with the outlook we envisaged for the year
Subscribe To Our Newsletter & Stay Updated